Clinical features and characteristics of Clostridium difficile PCR-ribotype 176 infection: results from a 1-year university hospital internal ward study by Jiri Drabek et al.
Drabek et al. Ann Clin Microbiol Antimicrob  (2015) 14:55 
DOI 10.1186/s12941-015-0114-0
SHORT REPORT
Clinical features and characteristics 
of Clostridium difficile PCR-ribotype 176 
infection: results from a 1-year university 
hospital internal ward study
Jiri Drabek1, Otakar Nyc2, Marcela Krutova2,3, Jan Stovicek1, Jana Matejkova2 and Radan Keil1*
Abstract 
Background: Clostridium difficile infection (CDI) is a major cause of antibiotic-associated diarrhoea. Given an increas-
ing CDI incidence and global spread of epidemic ribotypes, a 1-year study was performed to analyse the molecular 
characteristics of C. difficile isolates and associated clinical outcomes from patients diagnosed with CDI in the Internal 
Medicine department at University Hospital Motol, Prague from February 2013 to February 2014.
Results: A total of 85 unformed stool samples were analysed and CDI was laboratory confirmed in 30 patients (6.8 
CDI cases per 10,000 patient bed days and 50.6 CDI cases per 10,000 admissions). The CDI recurrence rate within 
3 months of treatment discontinuation was 13.3% (4/30). Mortality within 3 months after first CDI episode was 26.7% 
(8/30), with CDI the cause of death in two cases. 51.9% of C. difficile isolates belonged to PCR-ribotype 176. MLVA of 
ribotype 176 isolates revealed two clonal complexes formed by 10/14 isolates. ATLAS scores and Horn’s index were 
higher in patients with ribotype 176 infections than with non-ribotype 176 infections.
Conclusion: This study highlights the clinical relevance of C. difficile PCR-ribotype 176 and its capacity to spread 
within a healthcare facility.
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Findings
Background
Clostridium difficile infection (CDI) is a major cause of 
antibiotic-associated diarrhoea and a significant burden 
to healthcare services worldwide [1]. Results of a pan-
European epidemiological study in 2008 indicated that 
the Czech Republic has a relatively low CDI incidence 
(1.1 per 10,000 patient bed-days and 7.0 per 10,000 hos-
pital admissions) [2], although a recent epidemiological 
study suggested a CDI incidence rate of 4.4 and 6.2 cases 
per 10,000 patient bed-days in 2011–12 and 2012–13, 
respectively [3].
In 2013, the high prevalence of PCR-ribotype 176 
(n = 251; 40 %) was revealed by ribotyping of 624 C. diffi-
cile isolates from 11 Czech healthcare facilities [4] C. dif-
ficile ribotype 176 is thought to share many similarities 
to ribotype 027 [5–7] and it has been suggested that this 
type may be misdiagnosed as a ribotype 027 infection [8]. 
The long-term epidemic occurrence of C. difficile PCR-
ribotype 176 was also reported in Poland [9, 10].
In response to the reported unfavourable global CDI 
epidemiological situation, including in Czech Republic, 
a 1-year study was initiated to monitor the incidence of 
CDI, clinical features and outcomes and to investigate 
the molecular characteristics of C. difficile isolates in 
patients with CDI hospitalised in the Internal Medicine 
department of University Hospital Motol, Prague, Czech 
Republic, from February 2013 to February 2014.
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Microbiological testing
Stool samples of 85 patients aged ≥18 years with three 
or more unformed stools per day were investigated at 
the Department of Medical Microbiology. CDI was 
laboratory diagnosed using the C. difficile Quik Chek 
Complete® test (Alere) and C. difficile Alere and simul-
taneous toxin A/B positivity was detected in 24 sam-
ples (80 %). In six samples that were only GDH-positive 
but where patients had relevant clinical symptoms, the 
presence of toxigenic C. difficile was confirmed using 
PCR (GeneXpert®, Cepheid). Positive stool samples 
(GDH and toxin positive; GDH positive, toxin negative 
and PCR positive) were cultured anaerobically, after an 
alcohol shock treatment, on selective media (Oxoid); 
anaerobic culture was positive for C. difficile in 27/30 
samples (90  %). Antibiotic susceptibility of C. difficile 
isolates to metronidazole and vancomycin was deter-
mined by E-test® (BioMérieux) and minimum inhibi-
tory concentrations for all C. difficile isolates ranged 
from 0.03–2 mg/L for metronidazole and 0.015–1 mg/L 
for vancomycin (Table 1). No isolates were found to be 
resistant to either metronidazole or vancomycin.
C. difficile isolates molecular characterisation
PCR-ribotyping was performed according to the Stand-
ard Operating Protocol of ECDIS-net (http://www.
ecdisnet.eu) using capillary electrophoresis after PCR 
amplification with primers previously described by 
Stubbs et  al. [11]. Electrophoreograms were confirmed 
using the Webribo database [12]. PCR-ribotypes were 
identified for all 27 C. difficile isolates and 14 (51.9  %) 
belonged to ribotype 176. Other identified ribotypes 
were 012 (n = 2; 7.4 %), 014 (n = 2; 7.4 %), 001, 002, 005, 
017, 020, 049, 078, 434 and 015 (all n = 1; 3.7 %).
The presence of toxin genes was determined by multi-
plex PCR with specific primers for tcdA (toxin A), tcdB 
(toxin B), cdtA and cdtB (binary toxin) [13]. All C. dif-
ficile isolates revealed presence of genes for production 
of toxins A/B, while genes for production of binary toxin 
(cdtA/cdtB), which has been associated with increased 
attachment to epithelial cells, increased virulence and 
higher recurrence rates [14–16] were only found in iso-
lates of ribotypes 176 and 078 (15/27; 55.6 %). Summary 
of microbiological and molecular characteristics of C. 
difficile isolates is shown in Table 1.
The tcdC gene was amplified with primers C1 and C2 [17] 
and the obtained sequence was compared to NCBI refer-
ence sequence NC_009089.1. Two deletions (position 117, 
which introduces a frame-shift mutation leading to protein 
truncation [17], and 330–347) in the tcdC gene were found 
in all 14 ribotype 176 isolates. One isolate, ribotype 078, 
revealed 39-bp deletion from nucleotides 341–379 in the 
tcdC gene. No deletion in other 12 isolates was found. The 
precise function of the tcdC gene is not yet clear [18].
Genetic relatedness among C. difficile ribotype 176 
isolates was achieved using multi-locus-variable tandem 
repeats-analysis (MLVA). The number of tandem repeats 
were determined by Sanger sequencing in five previously 
published variable tandem repeat (VNTR) loci (A6Cd, 
B7Cd, C6Cd, G8Cd) [19, 20] and CDR60 [21]. A Mini-
mum Spanning Tree (MST) was created by Bionumerics 
v5.0 (Applied Maths) using a Manhattan coefficient to 
calculate the summed tandem repeat difference (STRD). 
A cluster analysis using the categorical distance and 
unweighted pair group method with arithmetic mean 
algorithms was also applied. The number of tandem 
repeats for each locus is summarised in Fig. 1. MST iden-
tified two clonal complexes when STRD ≤1 (Fig. 2). The 
first clonal complex was formed from eight isolates (55, 
269, 351, 263, 273, 279, 294 and 308). The second clonal 
complex consisted of two isolates (336 and 322). Between 
clonal complexes one and two, STDR  =  6 were found. 
Isolate 248 revealed STDR = 9 to isolate 294 (CC1), iso-
late 259 showed STDR = 5 to isolate 336 (CC2), isolate 
316 showed STDR = 6 and isolate 303 STDR = 9 to iso-
late 322 (CC2).
The time intervals of hospitalisation of patients infected 
by C. difficile ribotype 176 did not overlap except for two 
patients. This finding suggests that the probable source of 
infection may have come from the hospital environment 
and, given the high incidence of this ribotype previously 
reported in the Czech Republic [4], it is possible that 
ribotype 176 is endemic in the country and this type has 
Fig. 1 A Categorical MLVA of C. difficile ribotype 176 isolates (Bionu-
merics v5.0, Applied Maths)
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been introduced into the hospital environment on several 
occasions.
Clinical and epidemiological data analysis
CDI was diagnosed in 30 patients (female n = 13, male 
n = 17; mean age 69.0 years). The overall CDI incidence 
in the Internal Medicine ward during the study period 
was calculated as 6.8 CDI cases per 10,000 patient bed-
days and 50.6 CDI cases per 10,000 admissions which 
indicated a higher CDI incidence compared with recently 
reported rates [3].
Healthcare-associated CDI (HA-CDI) was diagnosed 
in 26 CDI cases (86.7 %) and community-associated CDI 
(CA-CDI) was diagnosed in four CDI cases (13.3  %). 
Severe CDI was diagnosed in 17 (56.7 %) patients accord-
ing to the Horn’s index [22, 23] and 18 (60 %) according to 
the ATLAS score [24]. Antibiotic treatment prior to CDI 
diagnosis was noted for 83.3  % (25/30) of patients. The 
most commonly used antibiotics were aminopenicillins 
with beta-lactamase inhibitors (n  =  12), fluoroquinolo-
nes (n =  12), broad-spectrum cephalosporins (n =  11), 
carbapenems (n  =  4), piperacillin–tazobactam (n  =  3) 
and aminoglycosides (n  =  3). Administered CDI treat-
ments, according to valid guidelines at the time of the 
study [25], were metronidazole (n = 10; 33.3 %), vanco-
mycin (n = 3; 10.0 %), combined metronidazole and van-
comycin (n = 13; 43.3 %), and metronidazole with other 
therapies (n =  1; 3.3  %). Three patients did not receive 
treatment for CDI. CDI recurrence within 3  months of 
treatment discontinuation was observed in 13.3 % (4/30) 
of patients and two received faecal transplant for recur-
rent disease. Mortality within 3  months after first CDI 
episode was 26.7 % (8/30); CDI was the cause of death in 
two cases 6.7 % (2/30) (Table 2).
To assess the association between C. difficile ribotype 
and disease severity, the clinical outcomes of patients 
with ribotype 176 infections were compared to those with 
other ribotype infections (Table  3). Analysis of ATLAS 
scores and the Horn’s index found that 11/14 (78.6  %) 
patients with ribotype 176 infections had an ATLAS 
score of 6–9 or a Horn’s index score of 3 or 4 compared 
with 6/13 (46.2 %) and 7/13 (53.9 %) of patients with non-
ribotype 176 infections. Furthermore, the mortality rate 
appeared to be higher in patients with ribotype 176 infec-
tions compared with non-ribotype 176 infections (35.7 
versus 15.4  %). No significant ribotype-associated dif-
ferences were noted in recurrence rates, ICU admission 
rates or prior antibiotic use (Table 3).
Clostridium difficile ribotype 027 strains are often 
thought to be associated with CDI outbreaks of increased 
disease severity [1, 5], but the clinical severity associated 
with ribotype 176 infections has not yet been studied in 
detail with exception of clinical data on ten patients, of 
whom 50 % had severe form of CDI, reported by Obuch-
Woszczatyński et  al. [9]. Our finding of a trend towards 
increased Horn’s index and ATLAS scores in patients with 
Fig. 2 A Minimum Spanning Tree of C. difficile ribotype 176 isolates (Bionumerics v5.0, Applied Maths). The numbers in the circles represent C. difficile 
PCR-ribotype 176 isolate number. The numbers in the lines represent the sum of tandem repeat differences between isolates
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ribotype 176 infections compared with non-ribotype 176 
infections provides some evidence to support the clinical 
importance of this ribotype. However, the small sample 
size of patients in this study indicates a need for further 
studies, incorporating a larger number of patients, to 
better understand the relative virulence of ribotype 176. 
The high incidence of epidemic C. difficile PCR-ribotype 
176 in our study emphasises the importance of imple-
menting continuous surveillance programmes for CDI at 
national and European level, including PCR ribotyping.
Table 1 Microbiological and molecular characteristics of C. difficile isolates
GDH glutamate dehydrogenase, MIC minimum inhibitory concentration
a Toxin A/toxin B/binary toxin
b Primers used to amplify tcdA are located upstream of the repetitive region in the 3′-end. The TcdA-negative strains due to 3′-end deletion revealed positive PCR 
amplification [13]














1 n/a + + – n/a n/a n/a n/a
2 259 + + + 176 A/B/bin 0.25 0.25
3 263 + + + 176 A/B/bin 0.25 0.25
4 269 + + + 176 A/B/bin 0.5 0.5
5 205 + + – n/a n/a n/a n/a
6 273 + + + 176 A/B/bin 0.6 0.25
7 298 + – + 049 A/B 1 0.5
8 280 + + – n/a n/a n/a n/a
9 279 + + + 176 A/B/bin 1 0.25
10 294 + + + 176 A/B/bin 0.12 1
11 303 + + + 176 A/B/bin 0.25 0.5
12 277 + – + 001 A/B 0.5 0.5
13 304 + + + 014 A/B 0.25 0.5
14 44 + – + 002 A/B 0.25 0.5
15 307 + + + 017 A/B 0.25 0.25
16 308 + + + 176 A/B/bin 0.25 0.25
17 316 + + + 176 A/B/bin 0.5 0.25
18 320 + – + 012 A/B 0.5 0.5
19 319 + + + 012 A/B 0.5 0.12
20 322 + + + 176 A/B/bin 0.5 2
21 365 + – + 176 A/B/bin 0.5 2
22 323 + + + 020 A/B 0.5 0.5
23 325 + + + 015 A/B 0.5 0.25
24 331 + + + 078 A/B/bin 0.5 0.25
25 336 + + + 176 A/B/bin 0.5 1
26 351 + + + 176 A/B/bin 0.25 1
27 365 + – + 014 A/B 0.5 0.5
28 391 + + + 005 A/B 0.25 0.5
29 388 + + + 434 A/B 0.25 0.12
30 248 + + + 176 A/B/bin 0.12 0.5
Page 5 of 6Drabek et al. Ann Clin Microbiol Antimicrob  (2015) 14:55 
Authors’ contributions
JD analysed and interpreted of data, drafted manuscript. ON co-designed and 
coordinated the study, supervised the microbiological part of the study, criti-
cal revised manuscript. MK carried out molecular analysis of isolates, drafted 
a part of the manuscript. JS analysed data, drafted the part of the manuscript. 
JM was responsible for bacteriological investigation of stool samples. RK 
designed and coordinated the study, supervised the clinical part of the study, 
critically revised the manuscript. All authors read and approved the final 
manuscript.
Author details
1 Department of Internal Medicine, 2nd Faculty of Medicine, Charles University 
in Prague and Motol University Hospital, 150 06, V Uvalu 84, Praha 5, Prague, 
Czech Republic. 2 Department of Medical Microbiology, 2nd Faculty of Medi-
cine, Charles University in Prague and Motol University Hospital, Prague, Czech 
Republic. 3 DNA Laboratory, Department of Paediatric Neurology, 2nd Faculty 
of Medicine, Charles University in Prague and Motol University Hospital, 
Prague, Czech Republic. 
Acknowledgements
Medical writing services were provided by David Burns on behalf of Astellas 
Pharma EMEA to assist with grammar and English translations. Astellas Pharma 
EMEA had no role in study design, data collection or the decision to publish 
the manuscript. We would like to thank Bohdana Hola for statistical analysis 
of data. The authors thank the ESCMID Study Group for Clostridium difficile 
(ESGCD) for their professional support. Molecular and microbiological analysis 
of C. difficile isolates was supported by the Ministry of Health, Czech Republic 
Internal Grant Agency NT/14209-3 and MH CZ-DRO, University Hospital Motol, 
Prague, Czech Republic 00064203.
Competing interests
The authors declare that they have no competing interests.
Received: 29 June 2015   Accepted: 22 November 2015
References
 1. Kuijper EJ, Coignard B, Tüll P, ESCMID Study Group for Clostridium difficile. 
EU Member States; European Centre for Disease Prevention and Control. 
Emergence of Clostridium difficile-associated disease in North America 
and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2–18.
 2. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, 
Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ, ECDIS Study Group. 
Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 
2011;377(9759):63–73. doi:10.1016/S0140-6736(10)61266-4.
 3. Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, Delmée 
M, Fitzpatrick F, Ivanova K, Kuijper E, Macovei IS, Mentula S, Mastrantonio 
P, von Müller L, Oleastro M, Petinaki E, Pituch H, Norén T, Nováková E, 
Nyč O, Rupnik M, Schmid D, Wilcox MH. Underdiagnosis of Clostridium 
difficile across Europe: the European, multicentre, prospective, biannual, 
point-prevalence study of Clostridium difficile infection in hospitalised 
patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014;14(12):1208–19. 
doi:10.1016/S1473-3099(14)70991-0.
 4. Krutova M, Nyc O, Kuijper EJ, Geigerova L, Matejkova J, Bergerova T, 
Arvand M. A case of imported Clostridium difficile PCR-ribotype 027 
infection within the Czech Republic which has a high prevalence 
of C. difficile ribotype 176. Anaerobe. 2014;30:153–5. doi:10.1016/j.
anaerobe.2014.09.020.
 5. Valiente E, Cairns MD, Wren BW. The Clostridium difficile PCR ribotype 027 
lineage: a pathogen on the move. Clin Microbiol Infect. 2014;20(5):396–
404. doi:10.1111/1469-0691.12619.
 6. Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW. Emergence of 
new PCR ribotypes from the hypervirulent Clostridium difficile 027 line-
age. J Med Microbiol. 2012;61(Pt 1):49–56. doi:10.1099/jmm.0.036194-0.
 7. Knetsch CW, Hensgens MP, Harmanus C, van der Bijl MW, Savelkoul PH, 
Kuijper EJ, Corver J, van Leeuwen HC. Genetic markers for Clostridium 
difficile lineages linked to hypervirulence. Microbiology. 2011;157(Pt 
11):3113–23. doi:10.1099/mic.0.051953-0.
 8. Krutova M, Matejkova J, Nyc O. C. difficile ribotype 027 or 176? Folia Micro-
biol (Praha). 2014;59(6):523–6. doi:10.1007/s12223-014-0323-5.
 9. Obuch-Woszczatyński P, Lachowicz D, Schneider A, Mól A, Pawłowska J, 
Ożdżeńska-Milke E, Pruszczyk P, Wultańska D, Młynarczyk G, Harmanus 
C, Kuijper EJ, van Belkum A, Pituch H. Occurrence of Clostridium difficile 
Table 2 Study population and  patient demographics 
(n = 30)
Patient characteristic N (%)
Male 17 (56.7)
Age ≥ 65 years 22 (73.3)
HA-CDI 26 (86.7)
CA-CDI 4 (13.3)
Recurrent CDI 4 (13.3)
Severe CDI—Horn’s index 17 (56.7)
Severe CDI—Atlas score 18 (60)
Mortality within 3 months 8 (26.7)
CDI cause of death 2 (6.7)
Previous hospitalisation 13 (59.1)
Previous antibiotic use 25 (83.3)
 Aminopenicillin/beta-lactamase inhibitors 12 (40)
 Cephalosporines 11 (36.7)
 Fluoroquinolones 12 (40)
 Carbapenems 4 (13.3)
 Piperacilin/tazobactam 3 (10)
 Aminoglycosides 3 (10)
Table 3 Comparison of  clinical outcomes in  patients 
grouped by isolated C. difficile PCR-ribotype





N % N %
Horn’s index
 1 1 7.7
 2 3 21.4 6 46.1
 3 9 64.3 5 38.5
 4 2 14.3 1 7.7
Atlas score
 1–2 2 15.4
 3–5 3 21.4 4 30.8
 6–7 9 64.3 5 38.5
 8–9 2 14.3 2 15.4
Recurrent CDI within 3 months  
of first episode (Yes)
2 14.3 2 15.4
CDI in 8 weeks prior to admission (Yes) 1 7.1 1 7.7
Admitted to ICU (Yes) 3 21.4 3 23.1
Antibiotic treatment within 1 month  
prior to admission (Yes)
12 85.7 10 76.9
Mortality within 3 months of first  
CDI episode (Yes)
5 35.7 2 15.4
Page 6 of 6Drabek et al. Ann Clin Microbiol Antimicrob  (2015) 14:55 
PCR-ribotype 027 and it’s closely related PCR-ribotype 176 in hospi-
tals in Poland in 2008–2010. Anaerobe. 2014;28:13–7. doi:10.1016/j.
anaerobe.2014.04.007.
 10. Pituch H, Obuch-Woszczatyński P, Lachowicz D, Wultańska D, Karpiński P, 
Młynarczyk G, van Dorp SM, Kuijper EJ. Hospital-based Clostridium difficile 
infection surveillance reveals high proportions of PCR ribotypes 027 
and 176 in different areas of Poland, 2011 to 2013. Euro Surveill. 2015;. 
doi:10.2807/1560-7917.ES.2015.20.38.30025.
 11. Stubbs SL, Brazier JS, O’Neill GL, Duerden BI. PCR targeted to the 16S–23S 
rRNA gene intergenic spacer region of Clostridium difficile and construc-
tion of a library consisting of 116 different PCR ribotypes. J Clin Microbiol. 
1999;37(2):461–3.
 12. Indra A, Schmid D, Huhulescu S, Hell M, Gattringer R, Hasenberger P, 
Fiedler A, Wewalka G, Allerberger F. Characterization of clinical Clostridium 
difficile isolates by PCR ribotyping and detection of toxin genes in 
Austria, 2006–2007. J Med Microbiol. 2008;57(Pt 6):702–8. doi:10.1099/
jmm.0.47476-0.
 13. Persson S, Torpdahl M, Olsen KE. New multiplex PCR method for 
the detection of Clostridium difficile toxin A (tcdA) and toxin B 
(tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Dan-
ish strain collection. Clin Microbiol Infect. 2008;4(11):1057–64. 
doi:10.1111/j.1469-0691.2008.02092.x.
 14. Stewart DB, Berg A, Hegarty J. Predicting recurrence of C. difficile colitis 
using bacterial virulence factors: binary toxin is the key. J Gastrointest 
Surg. 2013;17(1):118–24. doi:10.1007/s11605-012-2056-6 discussion 
p.124-5.
 15. Bacci S, Mølbak K, Kjeldsen MK, Olsen KE. Binary toxin and death after 
Clostridium difficile infection. Emerg Infect Dis. 2011;17(6):976–82. 
doi:10.3201/eid/1706.101483.
 16. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, 
Wehland J, Aktories K. Clostridium difficile toxin CDT induces formation 
of microtubule-based protrusions and increases adherence of bacteria. 
PLoS Pathog. 2009;5(10):e1000626. doi:10.1371/journal.ppat.1000626.
 17. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus 
and polymorphism in the putative negative regulator of toxin produc-
tion (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol. 
2002;40(9):3470–5.
 18. Bakker D, Smits WK, Kuijper EJ, Corver J. TcdC does not significantly 
repress toxin expression in Clostridium difficile 630ΔErm. PLoS One. 
2012;7(8):e43247. doi:10.1371/journal.pone.0043247.
 19. van den Berg RJ, Schaap I, Templeton KE, Klaassen CHW, Kuijper EJ. 
Typing and subtyping of Clostridium difficile isolates by using multiple-
locus variable-number tandem-repeat analysis. J J Clin Microbiol. 
2007;45(3):1024–8.
 20. Goorhuis A, Legaria MC, van den Berg RJ, Harmanus C, Klaassen 
CH, Brazier JS, Lumelsky G, Kuijper EJ. Application of multiple-locus 
variable-number tandem-repeat analysis to determine clonal 
spread of toxin A-negative Clostridium difficile in a general hospital 
in Buenos Aires. Argent Clin Microbiol Infect. 2009;15(12):1080–6. 
doi:10.1111/j.1469-0691.2009.02759.x.
 21. Marsh JW, O’Leary MM, Shutt KA, Pasculle AW, Johnson S, Gerding DN, 
Muto CA, Harrison LH. Multilocus variable-number tandem-repeat analy-
sis for investigation of Clostridium difficile transmission in hospitals. J Clin 
Microbiol. 2006;44(7):2558–66.
 22. Arora V, Kachroo S, Ghantoji SS, DuPont HL, Garey KW. High Horn´s index 
score predicts poor outcomes in patients with Clostridium difficile infec-
tion. J Hosp Infect. 2011;79(1):23–6. doi:10.1016/j.jhin.2011.04.027.
 23. Horn SD. Measuring severity of illness: comparisons across institutions. 
Am J Public Health. 1983;73(1):25–31.
 24. Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, Kean Y, Sears 
P. Derivation and validation of a simple clinical bedside score (ATLAS) for 
Clostridium difficile infection which predicts response to therapy. BMC 
Infect Dis. 2013;13:148. doi:10.1186/1471-2334-13-148.
 25. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiol-
ogy and Infectious Diseases. European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID): treatment guidance document for 
Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067–
79. doi:10.1111/j.1469-0691.2009.03099.x.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
